Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

医学 内科学 多发性骨髓瘤 肿瘤科 自体干细胞移植 回顾性队列研究 队列 硼替佐米
作者
Huishou Fan
出处
期刊:Cancer biology and medicine [Cancer Biology and Medicine]
卷期号:20 (1): 77-87 被引量:6
标识
DOI:10.20892/j.issn.2095-3941.2022.0612
摘要

Evidence on the prognostic value of autologous stem cell transplantation (ASCT) and minimal residual disease (MRD) dynamics of patients with newly diagnosed multiple myeloma (NDMM) in China is limited. Our objective in the current study was to understand the current care paradigm and outcomes of these patients.This longitudinal cohort study used historical data from three top-tier hematologic disease care hospitals that contributed to the National Longitudinal Cohort of Hematological Diseases-Multiple Myeloma. Treatment regimens [proteasome inhibitor (PI)-, immunomodulatory drug (IMiD)-, PI+IMiD-based, and conventional], post-induction response, ASCT and MRD status, and survival outcomes [progression-free survival (PFS) and overall survival (OS)] were evaluated.In total, 454 patients with NDMM were included (median age, 57 years; 59.0% males) with a median follow-up of 58.7 months. The overall response rate was 91.0%, 83.9%, 90.6%, and 60.9% for PI-, IMiD-, PI+IMiD-based, and conventional regimens, respectively. Patients with ASCT during first-line therapy (26.2%) had a longer PFS and OS than patients who did not receive ASCT [median PFS, 42.9 vs. 21.2 months, P < 0.001; median OS, not reached (NR) vs. 65.8 months, P < 0.001]. The median OS was NR, 71.5, and 56.6 months among patients with sustained MRD negativity, loss of MRD negativity, and persistent MRD, respectively (P < 0.001). Multivariate analysis revealed that the lactic dehydrogenase level, International Staging System stage, extra-medullary disease, and upfront ASCT were independent factors in predicting OS among NDMM patients.Our study showed that novel agent-based regimens, first-line ASCT, and sustained MRD negativity were associated with a superior outcome for patients with NDMM in China (Identifier: NCT04645199).

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
2秒前
姜姜不姜就完成签到,获得积分10
2秒前
3秒前
贾克斯发布了新的文献求助10
3秒前
小白应助小白一个采纳,获得30
3秒前
磁控达人完成签到,获得积分10
4秒前
勤劳篮球发布了新的文献求助10
5秒前
丘比特应助小跳蚤采纳,获得10
5秒前
爆米花应助白色热干面采纳,获得10
5秒前
SciGPT应助q12采纳,获得10
5秒前
6秒前
woniurourou发布了新的文献求助10
8秒前
归海一刀完成签到,获得积分10
9秒前
木口完成签到,获得积分10
9秒前
84W1yX完成签到,获得积分10
10秒前
10秒前
11秒前
HUSH994完成签到,获得积分10
11秒前
青山发布了新的文献求助10
12秒前
勤奋幻柏发布了新的文献求助10
13秒前
儒雅八宝粥完成签到 ,获得积分10
13秒前
15秒前
16秒前
彭于晏应助黄小慧采纳,获得10
16秒前
桐桐应助seven采纳,获得10
17秒前
Singularity发布了新的文献求助10
17秒前
17秒前
17秒前
17秒前
18秒前
宁悦完成签到 ,获得积分10
18秒前
18秒前
科研通AI2S应助活力灵波采纳,获得10
19秒前
斯文蓉发布了新的文献求助10
19秒前
8R60d8应助horkjohn采纳,获得10
19秒前
今后应助hu采纳,获得10
20秒前
20秒前
濮阳冰海发布了新的文献求助10
20秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3248330
求助须知:如何正确求助?哪些是违规求助? 2891731
关于积分的说明 8268453
捐赠科研通 2559668
什么是DOI,文献DOI怎么找? 1388584
科研通“疑难数据库(出版商)”最低求助积分说明 650772
邀请新用户注册赠送积分活动 627744